Dephasium, Ltd. entered into an asset purchase agreement to acquire Dephasium Corp. (OTCPK:PYMB) from Selectcore Ltd. (TSXV:SCG) and others in a reverse merger transaction on March 5, 2013. Under the terms of the agreement, Dephasium Corp.

will acquire ANCILIA patent and trademark from Dephasium and will issue 70 million shares of its common stock as consideration. On closing of the transaction, Dephasium Corp. will continue to operate under the same name.

Also, Lucien Gerard AIM will be elected as an additional Director of the merged entity. The transaction is subject to filing an application with FINRA advising FINRA of the name change and requesting a symbol change and valuation of the assets satisfactory to Dephasium Corp.